Australian medical device company Signostics Ltd. has appointed Kevin Goodwin as its new CEO.
Goodwin, who has been based in Seattle, Wash., has 28 years of executive experience in the ultrasound industry, with 17 years as the CEO and founder of point-of-care device company Sonosite Inc.
As CEO of Sonosite, Goodwin led the company from its pre-revenue spinoff as a Nasdaq-listed company beginning in April 1998. Sonosite ultimately reached revenues of $300 million under Goodwin’s guidance.His tenure at Sonosite was credited with many notable achievements, including new market creation and long-term sales growth. Sonosite was acquired by FujiFilm in an all-cash transaction in 2012 for just under $1 billion.
Chairman of Signostics. David Keogh, said Goodwin's appointment was a "giant leap forward" for the company and created the chance to become a leading player in cutting-edge healthcare delivery in a rapidly developing sector.
“Kevin was instrumental in creating a new market space in the ultrasound industry and his experience will be critical in building new opportunities for Signostics and customers,” Keogh said. “The board, management team and Mr. Goodwin all share the same view that Signostics can be a platform for next generation innovation in medical ultrasound, offering significant improvements to healthcare delivery.”
Goodwin said he was "energized" by the opportunity.
“I’ve been immersing myself in new possibilities for medical ultrasound for nearly 20 years, and Signostics is the perfect place to be right now," Goodwin said. "There are so many opportunities to move ultrasound forward through innovation, and this has always been my passion. Signostics offers the perfect platform for new 'breakout innovations,' which will benefit medicine around the world.”
Signostics makes handheld ultrasound devices and bladder scanners. Products include the SignosRT ultrasound system and the SignosRT Bladder. The company has regulatory approvals in place for Australia, the United States, Canada, Japan, Singapore and Europe.